ClinVar Miner

Submissions for variant NM_000249.3(MLH1):c.380+1G>A (rs267607745)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000075679 SCV000106682 likely pathogenic Lynch syndrome 2019-06-21 reviewed by expert panel curation Interrupts canonical donor splice site
Invitae RCV000524296 SCV000284061 likely pathogenic Hereditary nonpolyposis colorectal neoplasms 2019-10-30 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 4 of the MLH1 gene. It is expected to disrupt mRNA splicing and likely results in an absent or disrupted protein product. Loss-of-function variants in MLH1 are known to be pathogenic. This particular variant has been reported in the literature in individuals affected with suspected Lynch syndrome (PMID: 15849733, 19072991). ClinVar contains an entry for this variant (Variation ID: 90191). In summary, donor and acceptor splice site variants are typically truncating (PMID: 16199547), and truncating variants in MLH1 are known to be pathogenic (PMID: 15713769, 24362816). However, without additional functional and/or genetic data, this variant has been classified as Likely Pathogenic.
GeneDx RCV000486012 SCV000567567 pathogenic not provided 2016-10-21 criteria provided, single submitter clinical testing This variant is denoted MLH1 c.380+1G>A or IVS4+1G>A and consists of a G>A nucleotide substitution at the +1 position of intron 4 of the MLH1 gene. This variant destroys a canonical splice donor site and is predicted to cause abnormal gene splicing, leading to either an abnormal message that is subject to nonsense-mediated mRNA decay or to an abnormal protein product. This variant, also published as MLH1 c.381G>A, has been reported in several individuals/families suspected to have Lynch syndrome (Scott 2001, Mangold 2005a, Mangold 2005b, Schofield 2009). Based on the current evidence, we consider this variant to be pathogenic.
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000075679 SCV000592356 pathogenic Lynch syndrome 2012-11-12 criteria provided, single submitter clinical testing
Ambry Genetics RCV001021188 SCV001182769 pathogenic Hereditary cancer-predisposing syndrome 2019-10-14 criteria provided, single submitter clinical testing Alterations at the canonical donor/acceptor sites (+/- 1, 2) without other strong (b-level) evidence supporting pathogenicity;Detected in individual satisfying established diagnostic critera for classic disease without a clear mutation;Rarity in general population databases (dbsnp, esp, 1000 genomes)
Constitutional Genetics Lab,Leon Berard Cancer Center RCV001249909 SCV001423926 pathogenic Lynch-like syndrome 2019-07-01 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.